MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market

30-Nov-2010 - USA

MDxHealth SA announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc..

Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation technology, for the scientific research market in exchange for an upfront fee plus royalties from future sales utilizing this technology. Other terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances